CVR 10048818Public limited company (A/S)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)GaltenFounded 1 Nov 2000
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Eurofins Genomics Denmark A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
66
CVR, Aug 2026
-3 (-4.3%) over 12 months
Gross profit
43.6M
DKK, annual report 2025
+18.5% on 2024
Result
-8.6M
DKK, annual report 2025
Equity
14.2M
DKK, annual report 2025
Eurofins Genomics LUX Holding SARL100% of capital and votes
Operating company
Dandex estimate: 66 employees registered in 2026Jacob Sickmann Ransborgsince 11 Jun 2018
Owners of 5% or more. CVR registers shares in bands, not exact figures.
100% of capital and votessince 1 May 2025
CVR 35039503100% of capital and votesnotified 1 May 202520 Feb 2013 to 1 May 2025
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Founded 1 Nov 2000.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 66 employees, 56 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 3 | 5 | 6 | 8 | 6 | 7 | 12 | 15 | No count | No count | No count | No count | 19 | 23 | 25 | 25 | 25 | 26 | 27 | 26 | 26 | 26 | 26 | 26 | 27 | 33 | 35 | 35 | 37 | 39 | 37 | 35 | 35 | 33 | 33 | 34 | 35 | 36 | 32 | 32 | 30 | 31 | 33 | 38 | 37 | 33 | 38 | 33 | 32 | 33 | 34 | 34 | 33 | 36 | 37 | 40 | 42 | 43 | 42 | 42 | 41 | 38 | 38 | 39 | 42 | 41 | 42 | 44 | 47 | 49 | 49 | 46 | 46 | 44 | 45 | 45 | 47 | 50 | 54 | 52 | 53 | 54 | 50 | 49 | 50 | 60 | 69 | 80 | 123 | 123 | 132 | 133 | 136 | 153 | 128 | 113 | 110 | 104 | 119 | 123 | 119 | 106 | 93 | 89 | 76 | 80 | 86 | 73 | 84 | 76 | 75 | 64 | 62 | 59 | 58 | 56 | 58 | 65 | 68 | 66 | 69 | 63 | 64 | 72 | 69 | 64 | 64 | 64 | 65 | 64 | 67 | 64 | 61 | 64 | 61 | 63 | 63 | 63 | 62 | 62 | 69 | 63 | 68 | 69 | 68 | 66 | 64 | 63 | 66 | 63 | 64 | 63 | 62 | 64 | 68 | 66 |
| FTE | 1 | 1 | 3 | 4 | 5 | 5 | 8 | 12 | 14 | 14 | 14 | 14 | 17 | 21 | 23 | 23 | 23 | 24 | 24 | 23 | 23 | 23 | 23 | 23 | 23 | 29 | 32 | 32 | 33 | 35 | 32 | 29 | 29 | 30 | 28 | 28 | 30 | 31 | 27 | 28 | 27 | 28 | 29 | 32 | 32 | 32 | 34 | 30 | 27 | 30 | 31 | 32 | 31 | 34 | 34 | 35 | 39 | 40 | 38 | 35 | 35 | 34 | 34 | 35 | 38 | 37 | 36 | 39 | 42 | 42 | 43 | 41 | 41 | 41 | 42 | 42 | 42 | 45 | 48 | 48 | 49 | 47 | 46 | 44 | 44 | 49 | 59 | 64 | 116 | 113 | 117 | 114 | 120 | 114 | 99 | 93 | 91 | 80 | 77 | 88 | 90 | 82 | 79 | 72 | 69 | 69 | 68 | 63 | 64 | 59 | 58 | 59 | 56 | 55 | 55 | 55 | 57 | 57 | 59 | 58 | 59 | 56 | 56 | 63 | 60 | 59 | 59 | 58 | 59 | 59 | 58 | 57 | 55 | 53 | 54 | 57 | 57 | 59 | 59 | 58 | 62 | 60 | 62 | 61 | 60 | 58 | 57 | 56 | 56 | 58 | 59 | 58 | 59 | 60 | 57 | 56 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 43.6M, Operating profit -8.5M, Result for the year -8.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 143.1M, Equity 14.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 104,253 | 27,206 | 17,331 | 36,823 | 43,634 |
| Operating profit | +42,386 | -14,872 | -23,101 | -9,084 | -8,464 |
| Result for the year | +32,351 | -12,918 | -20,742 | -12,812 | -8,644 |
| Equity | 49,855 | 15,936 | 17,796 | -4,144 | 14,212 |
| Total assets | 123,921 | 77,042 | 134,500 | 175,330 | 143,100 |
| Employees (average) | 101 | 68 | 56 | 62 | 64 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | 154.7% | -74% | -38.4% | 36.8% | 18.5% |
| EBITDA | 55,761 | -8,165 | -16,227 | -96 | 1,765 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | 140.5% | -32.7% | -17.7% | 0% | 3.2% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 14,234note 1 | 14,267note 1 | 20,849note 2 | 11,790note 2 | 9,651note 2 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Eurofins Genomics Denmark A/S:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseBonus issue from reserves | None | None | None | 550,000 | |
| IncreaseNot read from the announcement | None | None | None | 500,000 | |
| FoundingNot read from the announcement | None | None | None | 125,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital. 1 step could not be read that way and stand as registered.
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
38 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægter ændret: 16.05.2025
Nyt navn: Eurofins Genomics Denmark A/S
Nyt binavn: Eurofins Genomics Europe AgriGenomics Products & Services A/S
Slettede binavne: Eurofins Safer At Work Nordics A/S, EUROFINS GENOMICS HOLDING DENMARK A/S, Eurofins Genomics Denmark A/S
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 37315788 Eurofins Genomics Denmark A/S og CVR-nummer: 35039503 EUROFINS GENOMICS HOLDING DENMARK A/S, der samtidigt er opløst.
Vedtægter ændret: 01.05.2025
Nye binavne: EUROFINS GENOMICS HOLDING DENMARK A/S, Eurofins Safer At Work Nordics A/S, GENOSKAN A/S, Eurofins GenoSkan A/S, Eurofins Safer At Work Denmark A/S, Eurofins Genomics Denmark A/S, Eurofins Genomics A/S
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 10048818 Eurofins Genomics Europe AgriGenomics Products & Services A/S (fortsættende), der tillige driver virksomhed under navnene AROS Applied Biotechnology A/S, Eurofins Genomics Europe Genotyping A/S, CVR-nummer: 37315788 Eurofins Genomics Denmark A/S (ophørende), der tillige driver virksomhed under navnene Eurofins Genomics A/S og CVR-nummer: 35039503 EUROFINS GENOMICS HOLDING DENMARK A/S (ophørende), der tillige driver virksomhed under navnene Eurofins Safer At Work Nordics A/S, GENOSKAN A/S, Eurofins GenoSkan A/S, Eurofins Safer At Work Denmark A/S.
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 10048818 Eurofins Genomics Europe AgriGenomics Products & Services A/S, CVR-nummer: 37315788 Eurofins Genomics Denmark A/S og CVR-nummer: 35039503 EUROFINS GENOMICS HOLDING DENMARK A/S må antages at være tilstrækkeligt sikrede efter fusionen.
Vedtægter ændret: 10.12.2024
Bestyrelse:
Fratrådte:
Sonja Maria Wiedemann, den 29.02.2024.
Tiltrådte:
Ulrich August Werner Kühle, den 01.03.2024.
Vedtægter ændret: 09.03.2023
Nyt navn: Eurofins Genomics Europe AgriGenomics Products & Services A/S
Nyt binavn: Eurofins Genomics Europe Genotyping A/S
Bestyrelse:
Fratrådte:
Stefánia Pcolová, den 27.05.2021.
Tiltrådte:
Jacob Sickmann Ransborg, den 27.05.2021.
Bestyrelse:
Fratrådte:
Bruno Francis Claude Poddevin, den 17.07.2020.
Tiltrådte:
Michael Hadem, den 17.07.2020.
Ny adresse: Smedeskovvej 38, 8464 Galten
Ny kommune: Skanderborg
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 15.05.2019.
Tiltrådte:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Værkmestergade 2, 18., 8000 Aarhus C, den 15.05.2019.
Vedtægter ændret: 03.01.2019
Nyt navn: Eurofins Genomics Europe Genotyping A/S
Nyt binavn: AROS Applied Biotechnology A/S
Direktion:
Fratrådte:
Daniel Schougaard Langhoff (adm. dir), den 11.06.2018.
Tiltrådte:
Jacob Sickmann Ransborg (adm. dir), den 11.06.2018.
Bestyrelse:
Fratrådte:
Morten Melbye, den 31.12.2016.
Direktion:
Fratrådte:
Morten Melbye (adm. dir), den 31.12.2016.
Tiltrådte:
Daniel Schougaard Langhoff (adm. dir), den 01.01.2017.
Vedtægter ændret: 30.05.2016
Bestyrelse:
Tiltrådte:
Morten Melbye, den 30.05.2016.
Selskabet tegnes af den samlede bestyrelse eller af bestyrelsesformanden i forening med direktøren eller et bestyrelsesmedlem..
CVR-nummer:
10048818.
NAVN:
AROS APPLIED BIOTECHNOLOGY A/S.
Adresse: Palle Juul-Jensens Boulevard 82, 8200 Aarhus N.
Kommune: Århus.
Bestyrelse:
Fratrådte:
Lars Christian Caspersen, den 13.08.2015.
Tiltrådte:
Thomas Gjelsnes, den 13.08.2015.
CVR-nummer:
10048818.
NAVN:
AROS APPLIED BIOTECHNOLOGY A/S.
Adresse: Palle Juul-Jensens Boulevard 82, 8200 Aarhus N.
Kommune: Århus.
Bestyrelse:
Fratrådte:
Torben Falck Ørntoft, den 27.05.2015.
Revision:
Fratrådte:
AP STATSAUTORISEREDE REVISORER P/S, den 27.05.2015.
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Jens Chr.Skous Vej 1, 8000 Aarhus C, den 27.05.2015.
Ny adresse:
Palle Juul-Jensens Boulevard 82, 8200 Aarhus N.
Direktion:
Udtrådt af direktionen:
Brian Sørensen, den 01.09.2013.
Indtrådt i direktionen:
Morten Melbye (adm. dir), den 01.09.2013.
Vedtægter ændret:
20.02.2013.
Bestyrelse:
Fratrådt som formand, men forbliver i bestyrelsen: Torben Falck Ørntoft, den 20.02.2013.
Udtrådt af bestyrelsen:
Kurt Hedegaard Carstensen, den 20.02.2013, Villy Helleskov, den 20.02.2013, Jørgen Winther Pedersen, den 20.02.2013, Niels Stampe Rüdiger, den 20.02.2013.
Indtrådt i bestyrelsen:
Adm. direktør Svend Aage Linde (formand), den 20.02.2013, Lars Christian Caspersen, den 20.02.2013, Bruno Francis Claude Poddevin, den 20.02.2013.
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller en direktør, af to bestyrelsesmedlemmer, eller af den samlede bestyrelse.
Revision:
Udtrådt af revisionen:
AP, STATSAUTORISEREDE REVISORER I/S, den 31.12.2012.
Indtrådt i revisionen:
AP STATSAUTORISEREDE REVISORER P/S, Oluf Palmes Allé 25 A, 1., 8200 Aarhus N, den 01.01.2013.
Erhvervsstyrelsen har modtaget spaltningsplan
for den påtænkte spaltning af
CVR-NR. 10048818 AROS APPLIED BIOTECHNOLOGY A/S.
De øvrige deltagende selskaber er et/flere
nye selskaber.
Kapitalejerne i.
CVR-NR. 10048818 AROS APPLIED BIOTECHNOLOGY A/S, har i enighed besluttet, at der ikke
skal udarbejdes en erklæring om kreditorernes stilling i
forbindelse med spaltningen. Kreditorer, hvis fordringer
er stiftet forud for bekendtgørelsen om spaltningen, og
for hvilke der ikke er stillet særskilt sikkerhed, kan
anmelde deres fordringer senest 4 uger efter at den
endelige beslutning om spaltningen er truffet.
Erhvervsstyrelsen har modtaget spaltningsplan
for den påtænkte spaltning af
CVR-NR. 10048818 AROS APPLIED BIOTECHNOLOGY A/S.
De øvrige deltagende selskaber er et/flere
nye selskaber.
Kapitalejerne i.
CVR-NR. 10048818 AROS APPLIED BIOTECHNOLOGY A/S, har i enighed besluttet, at der ikke
skal udarbejdes en erklæring om kreditorernes stilling i
forbindelse med spaltningen. Kreditorer, hvis fordringer
er stiftet forud for bekendtgørelsen om spaltningen, og
for hvilke der ikke er stillet særskilt sikkerhed, kan
anmelde deres fordringer senest 4 uger efter at den
endelige beslutning om spaltningen er truffet.
Vedtægter ændret:
24.09.2010.
Bestyrelse:
Udtrådt af bestyrelsen:
Carsten Kultoft Lorentsen, den 24.09.2010.
Revision:
Udtrådt af revisionen:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, den 24.09.2010.
Indtrådt i revisionen:
AP, STATSAUTORISEREDE REVISORER I/S, Olof Palmes Alle 25, 1., 8200 Århus N, den 24.09.2010.
Bestyrelse:
Fratrådt som formand, men forbliver i bestyrelsen: Carsten Kultoft Lorentsen, den 20.05.2009.
Indtrådt i bestyrelsen:
Læge Torben Falck Ørntoft (formand), den 20.05.2009, Managing Director Niels Stampe Rüdiger, den 20.05.2009.
Direktion:
Udtrådt af direktionen:
Torben Falck Ørntoft, den 20.05.2009.
Indtrådt i direktionen:
Adm. direktør Brian Sørensen (adm. dir), den 20.05.2009.
Ny adresse:
Brendstrupgårdsvej 102, 8200 Århus N.
Vedtægter ændret:
07.05.2007.
Kapitalforhøjelse:
kr. 50.000,00 indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 550.000,00.
Revision:
Udtrådt af revisionen:
PricewaterhouseCoopers I/S.
Indtrådt i revisionen:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, Jens Chr. Skous Vej 1, 8000 Århus C.
Bestyrelse:
Udtrådt af bestyrelsen:
Claus Thorsen, den 09.02.2007.
Indtrådt i bestyrelsen:
Advokat Carsten Kultoft Lorentsen (formand), den 09.02.2007.
Vedtægter ændret:
11.04.2005.
Kapitalforhøjelse:
kr. 375.000,00 indbetalt ved konvertering af gæld, kurs 100,00.
Selskabet er omdannet til et A/S med CVR-nr 10048818.
NAVN: AROS APPLIED BIOTECHNOLOGY A/S.
ADRESSE: c/o Østjysk Innovation A/S, Gustav Wieds Vej 10, 8000 Århus C.
Kommune:
Århus.
Kapital kr. 500.000,00.
Bestyrelse:
Villy Helleskov, Direktør Jørgen Winther Pedersen, Direktør Arne Josefsen Rolighed, Advokat Claus Thorsen.
Direktion:
Læge Torben Falck Ørntoft.
Selskabet tegnes af en direktør alene, to bestyrelsesmedlemmer eller af den samlede bestyrelse.
Revision:
PricewaterhouseCoopers Nobelparken, 8000 Århus C.
Regnskabsår:
01.01 - 31.12.
Bestyrelse:
Udtrådt af bestyrelsen:
Torben Falck Ørntoft, den 18.11.2003, Mogens Kruhøffer, den 18.11.2003.
Indtrådt i bestyrelsen:
Direktør Jørgen Winther Pedersen, den 18.11.2003, Direktør Arne Josefsen Rolighed, den 18.11.2003.
Bestyrelse:
Indtrådt i bestyrelsen:
Villy Helleskov, den 13.03.2002, Advokat Claus Thorsen, den 13.03.2002.
Stiftelsesdato:
01.11.2000.
Seneste vedtægtsdato:
01.11.2000.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 105,00.
Stiftere:
Læge Torben Falck Ørntoft, den 01.11.2000, Thomas Thykjær Andersen, den 01.11.2000, Mogens Kruhøffer, den 01.11.2000, CVR-NR. 20880341 ØSTJYSK INNOVATION A/S, c/o Forskerparken, Gustav Wieds Vej 10, 8000 Århus C, den 01.11.2000.
Bestyrelse:
Læge Torben Falck Ørntoft, den 01.11.2000, Formand Jørn Renz Enggaard, den 01.11.2000, Mogens Kruhøffer, den 01.11.2000.
Direktion:
Læge Torben Falck Ørntoft, den 01.11.2000.
Selskabet tegnes af to medlemmer af bestyrelsen i forening, af en direktør eller af den samlede bestyrelse.
Revision:
PricewaterhouseCoopers, 8000 Århus C, den 01.11.2000.
Første regnskabsår:
01.11.2000 - 31.12.2001.
Regnskabsår:
01.01 - 31.12.
P-number 1021102713Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
P-number 1026574834Terminalgade 1, 2770 Kastrup
P-number 1020757171Smedeskovvej 38, 8464 Galten
P-number 1008046634Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
P-number 1031229215Smedeskovvej 55, 8464 Galten
P-number 1026189019Brendstrupgårdsvej 21, 8200 Aarhus N
P-number 1026559126Brendstrupgårdsvej 23, 8200 Aarhus N
No other current company drawn.